DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Johnson - 1 Merck — - 1 Chris Schott - 1 Merck - 1 Schott - 1 — - 1 Regeneron - 1
Top related locs:
Mounjaro Novo Wells Fargo Trulicity Tirzepatide Danish Lilly Provo , Utah
Top related orgs:
JPMorgan - 2 Dow Jones - 1 Johnson - 1 Merck - 1 US Major Pharma - 1 Schott - 1 FactSet - 1 Pharmaceuticals - 1

Search resuls for: "Eli Lilly Pharmaceutical"


4 mentions found


☆ Here are JPMorgan's top drug stock picks into earnings
  + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com   time to read: +3 min
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.
Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo
☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
  + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +5 min
Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.
Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah
☆ Eli Lilly jumps to all-time highs on Alzheimer's news. Here's what it means our investment
  + stars: | 2023-04-21 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +6 min
LLY 1Y mountain Shares of Eli Lilly over the past 12 months. Still, a commercially successful Alzheimer's drug would be material for Eli Lilly and strengthen its long-term position. Mounjaro is the heart of our Eli Lilly investment case. Another catalyst looming for Eli Lilly shares is results from a study conducted by its competitor in the weight-loss category Novo Nordisk . Eli Lilly Pharmaceutical company logo SOPA Images | LightRocket | Getty Images
☆ Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites
  + stars: | 2022-11-18 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +5 min
Like the Club, Credit Suisse holds a positive view on Mounjaro — the company's diabetes drug that's shown immense promise as an obesity treatment, too — and Lilly's latest experimental Alzheimer's drug ahead of a pivotal data release expected next year. However, we differ on J & J, which will soon break itself up. The remaining J & J will be its current pharmaceutical and medical technologies divisions. Credit Suisse rates J & J as neutral with a $170 price target, which is nearly 4% below where the stock closed Thursday. A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.
0 next >>
Total: 4